Business, energy, technology, markets and global industry news from Business News Today

dermatology

PharmaDeviceNews dermatology
Turn Therapeutics is refining the Stage 2 design for GX-03 after early atopic dermatitis data showed rapid eczema responses alongside a notable vehicle effect. Representative image.
Pharma & Biotech

Turn Therapeutics moves to refine GX-03 as the atopic dermatitis evidence bar rises

Explore how Turn Therapeutics is refining the GX-03 Phase 2 trial after rapid eczema responses and a strong vehicle effect. Read what comes next.

Read More
Incyte’s Opzelura wins positive CHMP opinion for moderate atopic dermatitis in Europe
Pharma & Biotech

Incyte’s Opzelura wins positive CHMP opinion for moderate atopic dermatitis in Europe

The positive opinion moves ruxolitinib cream closer to a broader European label for adults inadequately controlled by standard topical therapies, opening a potential treatment position between conventional creams and systemic medicines.

Read More
A sterile ophthalmic vial in an eye exam setting highlights Saptalis Pharmaceuticals’ Cyclosporine Ophthalmic Emulsion 0.05% launch and growing generic dry eye treatment access. Representative image.
Pharma & Biotech

Can Saptalis Pharmaceuticals strengthen dry eye access with cyclosporine launch?

Find out how Saptalis Pharmaceuticals’ cyclosporine launch could reshape access, competition and generic dry eye treatment.

Read More
Representative image: A dermatologist discusses plaque psoriasis treatment with a patient, reflecting Akeso’s gumokimab approval and the intensifying IL-17 biologics race in China’s autoimmune disease market.
Pharma & Biotech

Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race

Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.

Read More
Representative image: A dermatologist examines an eczema flare, reflecting how EBGLYSS and other atopic dermatitis biologics are shifting the treatment conversation toward fewer injections, longer disease control, and lower patient burden.
Features & Analysis

How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy

Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.

Read More
Representative image: A clinician uses a handheld skin assessment device, reflecting DermaSensor’s CE Mark and the growing role of AI-assisted skin cancer triage in European primary care.
Pharma & Biotech

Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?

Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.

Read More
Representative image showing a clinical skin examination for actinic keratosis, as Rubedo Life Sciences reports early RLS-1496 data suggesting lesion reduction with minimal irritation in a Phase 1b/2a dermatology study.
Pharma & Biotech

Rubedo takes cellular rejuvenation into actinic keratosis with early RLS-1496 results

Rubedo’s RLS-1496 shows early actinic keratosis lesion reduction with low irritation. Find out why Phase 2b matters next.

Read More
Galderma wins FDA approval for Differin Epiduo OTC switch as acne treatment access expands
Pharma & Biotech

Why Galderma’s acne gel approval could quietly reset the over the counter dermatology market

Acne care is moving from prescription desks to retail shelves. Galderma’s Differin Epiduo switch tests how far OTC dermatology can go.

Read More
Representative image: A clinical research scene showing atopic dermatitis assessment, reflecting TRexBio’s TRB-061 development strategy as TNFR2 agonism and tissue Treg biology emerge as potential new approaches for treating moderate-to-severe inflammatory skin disease.
Pharma & Biotech

Could TRexBio’s Treg bet crack the next big frontier in atopic dermatitis?

Atopic dermatitis has more drugs, but not enough durable control. TRexBio’s TRB-061 tests whether tissue Tregs can change that.

Read More
Medical Devices & Diagnostics

Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth

Sensus settled the dispute, but the harder test is SRT adoption. Can reimbursement momentum turn into durable medtech growth?

Read More